Soluble CD147 in Plasma During Sepsis: Correlation with Disease Severity and Prognostic Implications
-
By
-
Jiaqi Chen
-
Hui Zhang
-
Yini Sun
-
Yukun Chang
-
Sheng Tu
-
Yang Xiao
-
Xiaowen Yu
-
Pan Wang
-
Zining Zhang
-
Yajing Fu
-
Qinghai Hu
-
Hong Shang
-
Yongjun Jiang
-
April 28, 2026
-
Clinical Scorecard: Soluble CD147 in Plasma During Sepsis: Correlation with Disease Severity and Prognostic Implications
At a Glance
| Category | Detail |
|---|
| Condition | Sepsis |
| Key Mechanisms | Elevated levels of soluble CD147 (sCD147) correlate with inflammatory responses and disease severity. |
| Target Population | Septic patients admitted to the ICU. |
| Care Setting | Intensive Care Unit (ICU) |
Key Highlights
- sCD147 levels significantly higher in septic patients compared to non-septic controls and healthy donors.
- sCD147 is an independent predictor of mortality in septic patients.
- Elevated sCD147 levels correlate with organ failure and inflammatory markers.
- Optimal cut-off for sCD147 predicting mortality is 805.20 pg/mL.
- sCD147 may serve as a promising biomarker for sepsis-related outcomes.
Guideline-Based Recommendations
Diagnosis
- Use sCD147 levels to differentiate septic patients from healthy individuals and non-septic ICU cases.
Management
- Consider monitoring sCD147 levels as part of the management strategy for septic patients.
Monitoring & Follow-up
- Regularly assess sCD147 levels to evaluate disease severity and prognosis.
Risks
- High sCD147 levels are associated with increased risk of mortality in septic patients.
Patient & Prescribing Data
Septic patients in the ICU.
sCD147 levels can guide prognostic assessments and potential therapeutic targets.
Clinical Best Practices
- Incorporate sCD147 measurement in routine assessments for septic patients.
- Utilize sCD147 levels in conjunction with SOFA scores for improved prognostic accuracy.
References
